RSS

nosocomial pneumonia

Swiss-based specialty pharma company, Polyphor, has announced that the first patient has been enrolled in the Phase III clinical trial for murepavadin — a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia more

News